新光藥業(300519.SZ):2019年度淨利潤升6.71%至9390.07萬元 擬10派4.5元
格隆匯4月20日丨新光藥業(300519.SZ)披露2019年年度報告,實現營業收入2.91億元,同比增長5.43%;歸屬於上市公司股東的淨利潤9390.07萬元,同比增長6.71%;歸屬於上市公司股東的扣除非經常性損益的淨利潤9009.79萬元,同比增長11.10%;基本每股收益0.59元,擬向全體股東每10股派發現金紅利4.5元(含税)。
報告期內,公司實現營業總收入2.91億元,較上年同期增長5.43%,報告期內,公司主導產品黃芪生脈飲、伸筋丹膠囊營業收入同比增長5.61%和9.32%,保健品西洋參口服液營業收入同比略有下降。報告期內,公司營業成本13,207.90萬元,較上年同期增加了6.10%。報告期內,公司銷售費用3046.77萬元、管理費用1658.49萬元、財務費用-1135.76萬元,三項費用較上年合計減少349.17萬元,較上年同期下降8.91%,主要系報告期內公司通過加強財務管理和現金管理,財務費用下降所致。報告期內,公司經營活動產生的現金流量淨額較上年同期增加549.39萬元,增長5.92%。
報告期內,公司主導產品為黃芪生脈飲、伸筋丹膠囊和西洋參口服液。其中,黃芪生脈飲收入佔比77.12%;伸筋丹膠囊佔比9.47%;西洋參口服液佔比10.82%。公司綜合毛利率為54.65%。報告期內,公司努力加大其他產品的市場培育力度,營業收入佔比較上年增長23.41%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.